Divisions of 1Medical Oncology and 2Surgical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova; 3Division of Medical Oncology, Ospedale S. Croce e Carle, Cuneo; 4Roche, Milano, Italy
Received 18 June 2001; revised 3 September 2001; accepted 20 September 2001.
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Capecitabine is an oral fluoropyrimidine with considerable activity and minimal myelosuppression and alopecia. This phase I study evaluated the addition of capecitabine to epirubicin/docetaxel combination therapy as first-line treatment for advanced breast cancer.
Patients and methods
Twenty-three female patients with advanced breast cancer received capecitabine (7651060 mg/m2 twice daily on days 114 of a 3-week treatment cycle) in combination with epirubicin and docetaxel (75 mg/m2 i.v. on day 1).
Results
The maximum tolerated dose of capecitabine was 985 mg/m2 and the principal dose-limiting toxicity was febrile neutropenia. No grade 3/4 anemia or thrombocytopenia occurred. There were no grade 4 non-hematological events and grade 3 events other than alopecia were rare. Alopecia occurred in all patients and treatment cycles, and asthenia occurred in all patients and in 84% of treatment cycles. Other frequent adverse events included nausea, vomiting, fever, paresthesia and elevated transaminase levels. An objective response to treatment was observed in 91% (95% confidence interval 72% to 99%) of patients.
Conclusions
The addition of capecitabine to docetaxel/epirubicin combination therapy provides a well-tolerated and active first-line chemotherapy regimen in patients with advanced breast cancer, and merits phase II/III evaluation.
Key words: advanced breast cancer, capecitabine, docetaxel, epirubicin, phase I
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Capecitabine (Xeloda®; F. Hoffmann-La Roche, Basel, Switzerland) is a novel, oral fluoropyrimidine carbamate, which was rationally designed to mimic continuous infusion 5-FU and generate 5-FU preferentially in tumor tissue through exploitation of high intratumoral concentrations of thymidine phosphorylase (TP) [9, 10]. Human pharmacokinetic studies have shown that capecitabine is rapidly and almost completely absorbed through the gastrointestinal wall, and is metabolized to 5-FU via a three-step enzymatic cascade [11]. The final step in the activation of capecitabine is mediated by TP, an enzyme that is highly active in tumor tissue compared with corresponding normal tissue [9]. The antitumor activity of capecitabine is enhanced by upregulation of TP activity, and preclinical studies have demonstrated synergy when capecitabine is combined with therapies that upregulate TP, including taxanes [12].
Capecitabine is an important agent for the treatment of patients with metastatic breast cancer who have exhausted all treatment options. In a phase II study of heavily pre-treated patients who had received prior paclitaxel therapy, capecitabine resulted in a 20% response rate and median survival of 12.8 months [13]. Four further studies in patients pre-treated with taxanes confirmed these results [1417]. Capecitabine has a safety profile that is typical of infused fluoropyrimidines. It is associated with a very low incidence of alopecia and myelosuppression. Promising results from two randomized phase II studies of capecitabine have demonstrated that the drug may also play a role in the first- and second-line treatment of metastatic breast cancer. Capecitabine monotherapy is active in anthracycline-resistant patients [18] and in previously untreated, post-menopausal women [19].
The activity of capecitabine, and the low incidence of myelosuppression, make it an attractive agent for incorporation into combination regimens. Furthermore, there is a clear rationale for combining capecitabine with agents known to upregulate TP activity in tumor tissue. A randomized phase III trial has recently demonstrated that capecitabine combined with docetaxel results in significantly superior tumor response rates, time to disease progression or death, and overall survival compared with docetaxel monotherapy in patients with anthracycline pre-treated, advanced breast cancer [20].
Previous studies have demonstrated that doxorubicin/docetaxel combination is an effective first-line treatment for patients with metastatic breast cancer [21, 22]. In a previous study, we demonstrated that epirubicin plus docetaxel, each administered at 75 mg/m2, is also a safe and active regimen in advanced breast cancer [23]. The principal dose-limiting toxicity (DLT) with this combination was febrile neutropenia.
The non-overlapping toxicity profiles, together with the observed synergic activity with docetaxel, suggest that capecitabine is an attractive agent for addition to the epirubicin/docetaxel combination regimen. The current phase I trial was undertaken to evaluate a triple combination of capecitabine, epirubicin and docetaxel as first-line therapy in patients with advanced breast cancer. The objectives of the study were to determine the maximum tolerated dose (MTD) and DLTs of oral capecitabine when administered twice daily according to the standard, intermittent schedule (2 weeks on treatment, 1 week off) in combination with intravenous epirubicin and docetaxel.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dose adjustments of capecitabine were based on the observed toxicity, and efforts were made to administer the full dose to all patients entered at the different levels. Patients that experienced higher than grade 1 non-hematological toxicity discontinued capecitabine until recovery to grade 1. Since capecitabine was not expected to worsen or unduly prolong the episode of neutropenia, its administration was continued throughout grade 3 or 4 neutropenic episodes. However, the administration of capecitabine was interrupted if any higher than grade 1 non-hematological toxicity co-incided with the neutropenic phase. Doses of capecitabine omitted due to toxicity were not replaced.
Duration of treatment depended on stage (III versus IV) and tumor response. Regardless of the stage, patients with progressive disease discontinued study treatment. Patients with stage III disease were treated with four to six cycles of chemotherapy, before local therapy (surgery and/or radiotherapy). Patients with stage IV disease were treated with up to eight cycles of chemotherapy.
Eligibility
The study included female patients with histologically or cytologically confirmed breast cancer with advanced disease (stage III or IV) who had received no prior chemotherapy for metastatic disease. Patients were required to meet the following additional criteria: age 1875 years, life expectancy >3 months, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, ANC 2000/µl, platelet count
100 000/µl, total bilirubin <1.5 times the upper normal limit (UNL), aspartate transaminase (AST) and/or alanine transaminase (ALT) <1.5 times UNL, alkaline phosphatase <2.5 times UNL (unless bone metastases were present in the absence of any liver disorders), creatinine concentrations <1.6 mg/dl (in cases of borderline concentrations, creatinine clearance
60 ml/min), and no evidence of other serious illness, medical condition, or symptomatic peripheral neuropathy with grade 2 (NCI CTC) or greater intensity. A normal left ventricular ejection fraction (LVEF) as measured by multiple gated acquisition (MUGA) scan or echocardiography was also required.
Patients were excluded from the study if they had received prior therapy for metastatic disease, previous docetaxel treatment in any setting, a cumulative epirubicin dose of >360 mg/m2, a cumulative doxorubicin dose of >200 mg/m2, concurrent treatment with experimental drugs in the 30 days prior to screening or concurrent treatment with corticosteroids used for reasons other than pre-medication (except chronic low-dose corticosteroid treatment: <20 mg/day used for 6 months). Other investigational drugs, other anticancer treatments, and prophylactic oral or intravenous antibiotics were prohibited during the study period. Hematopoietic growth factors were not permitted during the first treatment cycle, but during subsequent cycles could be administered as prophylactic treatment following febrile neutropenia or severe neutropenia lasting for >1 week in the previous cycle. All patients provided written informed consent.
Patient evaluation
Safety evaluation included history, physical examination, ECG and blood chemistry, performed every 3 weeks. Complete blood counts were performed at least twice weekly and in case of ANC <500/µl, daily. If clinically indicated, chest X-rays were performed every 3 weeks. An evaluation of LVEF was performed at baseline and every other cycle thereafter. Cardiac toxicity was defined as clinical signs and symptoms of congestive heart failure (CHF), a decrease in LVEF 45%, a decrease from baseline LVEF of
20 EF units, or a decrease in LVEF
10 EF units associated with a decline to a level of LVEF
50%. All adverse events were documented, including the nature, severity and outcome of the event. ECOG performance status was assessed every 3 weeks and tumor evaluation was performed at baseline and then every 6 weeks based on WHO criteria. The best overall response was defined as the best response recorded from the start of treatment to disease progression. Complete responses (CR; complete disappearance of all previously detectable disease for a period of at least 28 days, and no new lesions) and partial responses (PR; >50% reduction in the sums of the products of the biperpendicular diameters of all measurable disease for a period of at least 28 days, and no new lesions) were confirmed by a second tumor assessment after 4 weeks. The time to progression (TTP) was defined as the time from treatment initiation to progression, last contact or start of further antitumor therapy.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
DLTs and MTD
At dose level I, one patient experienced a DLT (according to the original protocol) during the first cycle (Table 2). This patient experienced grade 4 neutropenia on days 1113, accompanied by fever on days 12 and 13. The fever resolved without treatment modification and was not regarded as a DLT using the amended protocol specifying persistence of fever for >72 h. At dose level II, febrile neutropenia was recorded in two patients during the first cycle. However, in each case, fever persisted for <72 h and the patients continued therapy according to the amended protocol. Febrile neutropenia was also recorded in a patient receiving the first cycle of therapy at dose level III. In this patient, fever (38.238.5°C) persisted for 3 days and neutropenia (nadir 20/µl) resolved after 6 days without any adjustments to treatment, thus meeting the amended protocol definition of a DLT. At dose level IV, three patients experienced DLTs during the first treatment cycle. Grade 4 neutropenia (ANC <100/µl) occurred on day 9 in one patient and persisted for 5 days (nadir 9/µl). The patient recovered without capecitabine dose modification. A second patient experienced a grade 3 infection on day 15, which lasted for 8 days. The third patient experienced grade 3 mucositis on day 6 that persisted for 5 days. In this patient, capecitabine therapy was delayed for 2 days. All three patients treated at dose level IV (1060 mg/m2 twice daily) required prophylactic granulocyte-colony stimulating factor (G-CSF) and/or capecitabine dose reduction, and all experienced DLTs. Therefore, dose level III (capecitabine 985 mg/m2 twice daily, days 114, in combination with docetaxel and epirubicin, each administered at 75 mg/m2 on day 1 of each 21-day treatment cycle) was identified as the MTD. Five additional patients were treated at this dose level, and no further DLTs were observed. A total of 47 cycles were administered, with a median of six cycles (range three to eight) per patient. At this dose level, one patient received G-CSF starting from the second cycle.
|
|
|
|
Activity
An objective response (CR plus PR) to treatment was observed in 21 (95%) of the 22 patients evaluable for response (91% of the intent-to-treat population, 95% confidence interval, 72% to 99%), including one CR. Stable disease was recorded in the remaining evaluable patient. The median duration of follow-up, measured as the first day of treatment to last contact, was 23.2 months (range 2.634.2 months). Progressive disease was recorded in seven patients in the follow-up phase. Of these patients, six had metastatic disease at baseline, and only one had stage III disease. The median TTP was 19.5 months (range 2.634.2 months) in patients with metastatic disease, and was not meaningfully assessable in patients with locally advanced disease.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the present study, the MTD determined for the TEX regimen was capecitabine 985 mg/m2 twice daily for 14 days followed by a 7-day rest period, in combination with docetaxel and epirubicin, each administered at 75 mg/m2 on day 1 of each 21-day treatment cycle. As predicted from the known toxicity profile of docetaxel and epirubicin combination therapy, the predominant adverse events associated with this regimen were asthenia, nausea and neutropenia, and the principal DLT was febrile neutropenia. However, neutropenia did not require withdrawal from treatment in any patient, and concomitant administration of G-CSF prevented the recurrence of neutropenia in five of six patients receiving this prophylactic therapy as directed in the protocol. Typically, neutrophil levels were restored to baseline by the end of the 3-week regimen and there were no long-standing or cumulative effects of myelosuppression. There were no treatment-related deaths during the study.
The most frequent non-hematological toxicities were asthenia and nausea. Asthenia is a common complication of docetaxel administration, regardless of the dose used; an incidence of 65% was reported with the use of either 60 mg/m2 or 100 mg/m2 [27]. Asthenia is also observed with capecitabine monotherapy, and therefore the additive effect with the combination of capecitabine and docetaxel was predictable. In our study, although asthenia was recorded in all patients, the majority of cases were of only grade 1 or 2, with grade 3 as-thenia recorded in only two patients. Nausea has also been observed with capecitabine monotherapy [28], and in the present study was reported in nearly 50% of cycles. However, in our study anti-emetic therapy was given for a maximum of 3 days using corticosteroids and metoclopramide, both useful drugs for the prevention of delayed emesis. Therefore, in order to avoid side effects related to a long-term use of corticosteroids, metoclopramide may be a good candidate for the treatment of nausea induced by capecitabine. Adequate supportive care with both pharmacological and non-pharmacological interventions to better control asthenia and nausea may improve the tolerability of the TEX regimen, and should be used in future trials investigating this regimen. Other non-hematological adverse events were generally predictable, and treatment interruption and, if necessary, dose modification were effective in managing the majority of cases. Notably, grade 3 hand-foot syndrome was observed in only one patient. There were no grade 3/4 cardiotoxicities, indicating that anthracycline-induced cardiotoxicity was not potentiated.
The combination also demonstrated high antitumor activity. An objective response was observed in 95% of evaluable patients (91% of the intent-to-treat population). These results compare favorably with those of previous phase I studies, which have demonstrated response rates of 52% to 75% for docetaxel and epirubicin as first-line therapy in patients with advanced breast cancer [23, 2933].
In conclusion, TEX was shown to be a well-tolerated and active chemotherapy regimen in patients with advanced/metastatic breast cancer. The results of this trial support further evaluation of this triple combination in phase II/III studies in patients with advanced/metastatic breast cancer. The dose recommended for further evaluation is intermittent capecitabine 985 mg/m2 twice daily for 14 days followed by a 7-day rest period, in combination with docetaxel and epirubicin, each administered at 75 mg/m2 on day 1 of each 21-day treatment cycle.
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Gairard B, Mathelin C, Schaffer P et al. Breast cancer: epidemiology, risk factors, screening. Rev Prat 1998; 48: 2127.[Medline]
3.
Parker SL, Tong T, Bolden S et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 527.
4. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26 (Suppl 12): 110.[ISI][Medline]
5. Norton L. Salvage chemotherapy of breast cancer. Semin Oncol 1994; 21: 1924.
6. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 21972205.[Abstract]
7. Venturini M, Bruzzi P, Del Mastro L et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 764773.[Abstract]
8. Hortobagyi GM. Developments in chemotherapy of breast cancer. Cancer 2000; 88: 30733079.[Medline]
9. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 12741281.[ISI][Medline]
10. Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291297.[ISI][Medline]
11. Reigner B, Blesch K, Weidekamm E. Capecitabine; a review of its clinical pharmacokinetics. Clin Pharmacokinet 2001; 40: 85104.[ISI][Medline]
12. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 10131019.[Abstract]
13.
Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485493.
14. Blum JL, Buzdar AU, Dieras V et al. A multicenter phase II trial of XelodaTM (capecitabine) in taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 19: 107 (Abstr 403).
15. Reichardt P, von Mickwitz G, Luck HJ et al. Capecitabine: an active and well tolerated treatment option for patients with metastatic breast cancer recurring after taxane-containing chemotherapy. Results of a multicenter phase II trial. Breast Cancer Res Treat 2000; 64: 83.
16. Cervantes G, Torrecillas L, Erazo A et al. Capecitabine (Xeloda) as a treatment after failure to taxanes for metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19: 121 (Abstr 469).
17. Wong Z, Wong K, Chew L et al. Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC). Proc Am Soc Clin Oncol 2000; 19: 120 (Abstr 466).
18. OReilly SM, Moiseyenko V, Van Belle S et al. A randomised, phase II study of Xeloda® (capecitabine) versus paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol 1998; 17: 163a (Abstr 627).
19.
OShaughnessy J, Moiseyenko V, Bell D et al. A randomized phase II study of XelodaTM (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged 55 years. Proc Am Soc Clin Oncol 1998; 17: 103 (Abstr 398).
20. OShaughnessy J, Vukelja S, Moiseyenko V et al. Results of a large phase III trial of Xeloda/Taxotere® combination therapy vs Taxotere® monotherapy in metastatic breast cancer (MBC) patients. Poster presented at the San Antonio Breast Cancer Symposium 2000, San Antonio, USA.
21. Misset JL, Dieras V, Gruira G et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553560.[Abstract]
22. Nabholtz JM, Falkson G, Campos D et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. Proc Am Soc Clin Oncol 1999; 18: 127 (Abstr 485).
23. Venturini M, Michelotti A, Papaldo P et al. Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. Ann Oncol 2001; 8: 10971106.
24.
Chan S, Kay F, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 23412354.
25.
Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 14131424.
26. Sjöström J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 11941201.[ISI][Medline]
27. Docetaxel Prescribing Information, Aventis, January 2000.
28.
Blum JL. The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 2001; 6: 5664.
29. Kerbrat P, Viens P, Roché H et al. Docetaxel in combination with epirubicin as first-line chemotherapy of metastatic breast cancer: final results. Proc Am Soc Clin Oncol 1998; 17: 151 (Abstr 579).
30. Pagani O, Sessa C, Martinelli G et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999; 10: 539545.[Abstract]
31. Raab G, Borquez D, Harstrick A et al. Phase I study of docetaxel in combination with epirubicin as first line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 168 (Abstr 644).
32. Mavroudis D, Alexopoulos A, Ziras N et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 2000; 11: 12491254.[Abstract]
33. Trudeau ME, Crump M, Latreille J et al. Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I/II study of the National Institute of CanadaClinical Trials Group. Proc Am Soc Clin Oncol 1999; 18: 117 (Abstr 443).